|   | 
        
            
         | 
          | 
        
        
        
            | 
                
             | 
         
        
             | 
         
        
            
            
            
  
    
	  | 
   
  
    
        
          |   | 
          
              
                | 
                    µ¿¼º±×¸®¼¼¿ÀÇ®ºóÁ¤250mg  [Griseofulvin]  
                    
                 | 
               
              
                | 
                     Àü¹®ÀǾàǰ | ºñ±Þ¿©  
                        
                    	
                    
                 | 
               
              
                | 
					  
                  
				  
                 | 
               
              
              
              
              
              |   |  
              
                
                    
                        | 
                      ¾Ë¸²:  | 
                      µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. | 
                     
                    | 
               
            
              
                
                   
                   
                   
                   
		   
                 | 
               
              
                | 
                  
                  
                 | 
               
              | 
            | 
         
       
       | 
   
    |  
  
    | 
      
     | 
     
  |  
                              
                                  | 
                                   | 
                               
            
            
                
            
            
              
            
                            
              
                                                     
            
            
   |  
  
    | 
      
     | 
   
   
     | 
   
    
   
    | 
       
        À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
        ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
        À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
        ·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
       
     | 
   
  
     | 
   
   
  
    
      
	
	  
	     |  
	    
	      
	        
            
                | Çã°¡Á¤º¸ | 
                         
	         
	       | 
	     
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå  »óÇÑ±Ý¾× | 
    
      
      
        
        [A06702641]  
	    
	    
          [º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸] 
          
        
        
        
           \0 ¿ø/1Á¤(2002.05.11)(ÇöÀç¾à°¡)
            
           \50 ¿ø/1Á¤(2001.03.25)(º¯°æÀü¾à°¡)
              
	 
	   
	   
       
      
       
       
     
      
      
     
      
    
    
      
     [»óº´ÄÚµåÁ¶È¸]
      
     [Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
     [¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
     | 
   
   
    | ºü¸¥Á¶È¸ | 
    
      
     |   
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
      
        [Á¶È¸]
     | 
      
  
  
  
  
   
    | È¿´ÉÈ¿°ú | 
    
    [ÀûÀÀÁõ º° °Ë»ö] 
      
    
     
	 
      [À¯È¿±ÕÁ¾] 
   ÇǺλç»ó±Õ.
  
[ÀûÀÀÁõ] 
   1.ÁÖÈ¿´É¡¤È¿°ú 
     ÇǺÎ, ¸ð¹ß, ¼ÕÅé, ¹ßÅéÀÇ ¹é¼±°¨¿°Áõ(üºÎ¹é¼±, µÎºÎ¹é¼±, °íºÎ¹é¼±, °í¹é¼±, ¸ðâ) 
[Drugbank ÀÇ ¼ººÐÁ¤º¸¿¶÷] [Griseofulvin]
      
      
      
      
     | 
   
  
  
  
  
  
  
  
  
    
  
  
   
    | ¿ë¹ý¿ë·® | 
    
      * Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù. 
    
     
      
      
     [󹿾à¾î] 
      [ÁÖ¼ººÐÄÚµå:167502ATB ¿¡ µû¸¥ ½É»çÁöħ¿¶÷] 
¼ºÀÎ : ±×¸®¼¼¿ÀÇ®ºóÀ¸·Î¼  1ÀÏ 250-500mg(¿ª°¡)À» 1-¼öȸ ºÐÇÒ °æ±¸ Åõ¿©ÇÑ´Ù.  Áõ»ó¿¡   µû¶ó  ÃÖÃÊ 1000mg(¿ª°¡)À»  Åõ¿©Ç졒   È¿°ú°¡  ÀÖÀ¸¸é 250-500mg(¿ª°¡)À¸·Î °¨·® ÇÑ´Ù. 
¾î¸°ÀÌ : 1ÀÏ Ã¼Áß kg´ç 10mg (¿ª°¡)À» 1-¼öȸ ºÐÇÒ °æ±¸Åõ¿©ÇÑ´Ù. 
{üÁß 15-25kg 1ÀÏ 125-250mg(¿ª°¡)Åõ¿©} 
{üÁß 25kg 1ÀÏ 250-500mg(¿ª°¡)Åõ¿©} 
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.     
      	    
     | 
   
  
  
  
  
  
  
  
  
  
   
    | ±Ý±â | 
    
      - Æ÷¸£ÇǸ°Áõ ȯÀÚ
 - °£Àå¾Ö(°£¼¼Æ÷ºÎÀü)ȯÀÚ
 - ÀÌ ¾à¿¡ °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ
 - È«¹Ý¼º ·çǪ½º(LE) ȯÀÚ
 - ´ÙÇü »ïÃ⼺ È«¹Ý ȯÀÚ
 - Ç¥ÇDZ«»ç ȯÀÚ
 - ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀÎ
    
 
  | 
   
  
  
  
  
  
  
   
    | ÀÌ»ó¹ÝÀÀ | 
    
      -  °ú¹ÎÁõ :
   °ú¹ÎÁõ µå¹°°Ô Ç÷°ü½Å°æ¼º ºÎÁ¾, ±¤°¨¼ö¼ºÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
ÇǺΠ: µå¹°°Ô ¸®¿¤ÁõÈıº(Áßµ¶¼ºÇ¥ÇDZ«»çÁõ) ¶§¶§·Î ¹ßÁø, È«¹Ý, Àü½Å¼º È«¹Ý¼º ·çǪ½º(SLE), ´ÙÇü »ïÃ⼺ È«¹Ý, Ç¥ÇDZ«»ç, µÎµå·¯±â, ¹ÚÅ»¼º ÇǺο°,  »ö¼ÒÄ§Âø µîÀÇ Áõ»óÀÌ ÀϾ¼ö  ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇ졒  ÀÌ»óÀÌ ÀÎÁ¤µÇ´Â °æ¿ì´Â ÁßÁöÇÏ´Â µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
 Àü½Å¼º È«¹Ý¼º ·çÇÁ½º(SLE)¾ç Áõ»ó : µå¹°°Ô SLE¾ç Áõ»ó(¹ß¿, È«¹Ý, ±ÙÀ°Åë, °üÀýÅë, ¸²ÇÁÀý, ¿ËÁ¾µî)ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
 Ç÷¾× :  ¶§¶§·Î ¹éÇ÷±¸ °¨¼Ò, °ú¸³±¸  °¨¼Ò, ¹éÇ÷±¸Áõ°¡ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
°£Àå : ¶§¶§·Î GOTÀÇ Áõ°¡, BSP ¹è¼³Áö¿¬ µîÀÌ ³ªÅ¸³¯¼ö ÀÖ´Ù.
 ¼Òȱâ : ¶§¶§·Î  ½Ä¿åºÎÁø, ±¸¿ª, À§ÀåÀå¾Ö, ¾Æ±¸Ã¢, ±¸Åä, ¼³»ç, »óº¹ºÎºÒÄè°¨ µå¹°°Ô ¹Ì°¢ÀÌ»ó, ¼³Åë, ±¸°¥, À§Àå°ü ÃâÇ÷ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
 Á¤½Å½Å°æ°è : ¶§¶§·Î Çö±â, µÎÅë, µÎÁß, Á¹À½, ºÒ¸é, ÇÇ·Î µå¹°°Ô À̸í, Á¤½ÅÂø¶õ, ¿ì¿ï»óÅÂ, ½Ã·ÂÀå¾Ö, ¸»ÃʽŰ濰  µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç, Àå±â Åõ¿©½Ã ¼Õ°ú ¹ßÀÇ Áö°¢ÀÌ»óÀÌ ÀϾ ¼ö ÀÖ´Ù.
 ½ÅÀå : ¶§¶§·Î ´Ü¹é´¢, ½ÅÁõ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
 ´ë»çÀÌ»ó : µå¹°°Ô Æ÷¸£ÇǸ°ÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
 ±âŸ : ¶§¶§·Î ±Çۨ, ¹ß¿, °üÀýÅë, µå¹°°Ô ¿©¼ºÇü À¯¹æ, ¿ù°æÀÌ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
          
     | 
   
  
  
    
   
    | ÀϹÝÀû ÁÖÀÇ | 
    - ¿¹¹æÀû ¿ë¹ý
 
     °õÆÎÀÌ °¨¿°ÀÇ ¿¹¹æ¿¡ ´ëÇÑ ÀÌ ¾àÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀº ¾ÆÁ÷ È®¸³µÇ¾î  ÀÖÁö ¾Ê´Ù.
 - µ¿¹° µ¶¼º
 
     »ç·á¿¡ ÀÌ ¾àÀ»  0.5-2.5%ÀÇ ³óµµ·Î ³Ö¾î Á¤±âÀûÀ¸·Î Áã¿¡ Åõ¿©ÇÏ¿´À» ¶§ ¿©·¯ Á¾·ùÀÇ Áã¿¡¼ °£ Á¾¾çÀÌ »ý°åÀ¸¸ç ƯÈ÷ ¼öÄÆµé¿¡¼ ÇöÀúÇÏ°Ô ³ªÅ¸³µ´Ù. Áã ¿¡¼ °£±«»ç, °£¿°ÀÌ º¸°íµÇ¾î ÀÖ´Ù. ÀÌ ¾àÀ»  ¾ÆÁÖ ¹Ì¼¼ÇÑ ÀÔÀÚ·Î Åõ¿©ÇÏ¿´À»  ¶§ È¿·ÂÀÌ ÃËÁøµÇ´Â °á°ú¸¦ ¾ò¾ú´Ù. Ãâ»ýÈÄ ÃÖÃÊ 3ÁÖµ¿¾È ºñ±³Àû ÀûÀº ¾çÀ» ÁÖ 1ȸ ÇÇÇÏÁÖ»ç ÇÏ¿´À» ¶§  °£¾ÏÀÌ »ý°å´Ù´Â º¸°í°¡ ÀÖÀ¸¸ç  ´Ù¸¥ µ¿¹°¿¡ ´ëÇÑ ½ÇÇè¿¡¼´Â Á¾¾ç¹ß»ýÀÇ Áõ°Å¸¦ ¾òÁö ¸øÇÏ¿´´Ù. ¾Æ±Þ¼º µ¶¼º½ÃÇè¿¡¼´Â °æ±¸Åõ¿©ÇÏ¿´À» ¶§ Áã¿¡¼ °£¼¼Æ÷ ±«»ç¸¦ ¾ß±â½ÃÄ×À¸³ª, ´Ù¸¥ µ¿¹°¿¡¼´Â º¼ ¼ö ¾ø¾ú´Ù. ÀÌ ¾àÀ» Åõ¿©ÇÑ ½ÇÇ赿¹°¿¡¼ Æ÷¸£ÇǸ° ´ë»çÀå¾Ö°¡ ³ªÅ¸³µ´Ù. ÀÌ ¾àÀº µ¿¹°½ÇÇè¿¡¼ À¯»çºÐ¿½Ã ÄÝÄ¡½Å¾ç È¿°ú¸¦ ³ªÅ¸³»°í ÇǺÎÁ¾¾ç À¯µµ½Ã ¸ÞÆ¿ÄݶõÆ®¸°°ú ÇÔ²² °øµ¿¹ß¾Ï¼ºÀ» ³ªÅ¸³½´Ù´Â º¸°í°¡ ÀÖ´Ù.
 - »ý½Ä¿¡ ´ëÇÑ ¿¬±¸
 
     ÀÓ½ÅÇÑ Áã¿¡  °æ±¸Åõ¿©½Ã žƵ¶¼º°ú ±âÇü¹ß»ýÀÇ  º¸°í°¡ ÀÖ´Ù.  µ¿¹°  »ý½Ä ½ÇÇè¿¡ ´ëÇÏ¿©´Â °è¼Ó ¿¬±¸ÁßÀ̸ç Áã¿¡¼ Á¤ÀÚ ¹ß»ýÀÇ ¾ïÁ¦°¡ ÀÖ¾ú´Ù´Â º¸°í°¡ ÀÖÀ¸¸ç ¼¼Æ÷³»  À¯Àü¹°Áú¿¡ ÇØ¸¦ ÀÔÈú ¼ö ÀÖ´Ù. ƯÈ÷  ³²ÀÚÀÇ °æ¿ì¿¡´Â  Á¤ÀÚ¿¡ ¿µÇâÀ» ÁֹǷΠ º¹¿ëÈÄ 6°³¿ù°£ ÇÇÀÓÇØ¾ß ÇÑ´Ù.
 - Àå±â Åõ¿©½Ã´Â Á¤±âÀûÀ¸·Î °£±â´É, ½Å±â´É, Ç÷¾× µîÀÇ °Ë»ç¸¦ ÇÏ´Â °Í ÀÌ ¹Ù¶÷Á÷ÇÏ´Ù. 
 - ÀÌ ¾à Åõ¿©Áß Á¡Â÷ Å»¶ôµÇ¾î °¡´Â ÇǺλç»ó±ÕÀÌ ºÎÂøµÇ¾î ÀÖ´Â ÄɶóƾÀ» ó¸®Çϱâ À§ÇÏ¿© Àû´çÇÑ ±¹¼Ò¿ä¹ýÀÇ º´¿ëÀÌ ÇÊ¿äÇÏ´Ù.
 - Á¹À½, ÁýÁß·Â ÀúÇÏ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ ¾àÀ» Åõ¿©ÁßÀΠȯÀÚ´Â ÀÚµ¿Â÷ÀÇ ¿îÀüµî À§ÇèÀ» ¼ö¹ÝÇÑ ±â°èÁ¶ÀÛ¿¡ Á¾»çÇÏÁö ¾Êµµ·Ï ÇÑ´Ù.
 
  | 
   
  
  
  
    
   
    | »óÈ£ÀÛ¿ë | 
    - ÀÌ ¾àÀº ¾ËÄÚ¿ÃÀÇ  ÀÛ¿ëÀ» Áõ°ÇÏ°í ¶Ç Äí¸¶¸°°è(¿Í¸£ÆÄ¸°°è)Ç×ÀÀÇ÷ÀÇ ÀÛ¿ëÀ» ¾àÈÇϹǷΠÀ̵é°ú º´¿ëÅõ¿©½Ã ¿ë·®¿¡ ÁÖÀÇÇÑ´Ù.
 - ¹Ù¸£ºñÅ»»ê À¯µµÃ¼¿ÍÀÇ º´¿ëÅõ¿©½Ã ÀÌ ¾àÀÇ ÀÛ¿ëÀÌ ÀúÇϵǹǷΠ¿ë·®¿¡ ÁÖÀÇÇÑ´Ù.
 - °æ±¸¿ë Ȳü.³Æ÷ È£¸£¸ó°úÀÇ º´¿ëÅõ¿©½Ã ±× ÀÛ¿ëÀ» °¨¼Ò½ÃŲ´Ù´Â º¸°í°¡ ÀÖ´Ù.
 
  | 
   
  
  
  
   
    | ÀӺο¡ ´ëÇÑ Åõ¿© | 
    
      
	[ÀӺαݱ⠼ººÐ Á¶È¸]       
      À¯»ê, ±âÇü¾Æ Ãâ»êÀÇ ÀÓ»ó¿¹°¡ º¸°íµÇ°í µ¿¹°½ÇÇè(·§Æ®)¿¡¼µµ ÃÖ±âÇüÀÛ¿ëÀÌ º¸°íµÇ°í ÀÖÀ¸¹Ç·Î ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀο¡´Â Åõ¿©ÇÏÁö ¸» °Í.
     | 
   
  
  
  
  
   
    | ¼öÀ¯ºÎ¿¡ ´ëÇÑ Åõ¿© | 
    ¸ðÀ¯·ÎÀÇ ÀÌÇàÀº º¸°íµÇ¾î ÀÖÁö ¾ÊÀ¸³ª ¼öÀ¯ÁßÀÎ ¾î¸°ÀÌ¿¡ ´ëÇÑ ¾ÈÀü¼ºÀº È®¸³µÇ¾î ÀÖÁö ¾Ê´Ù. | 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  		
  
  	
  
  
    
   
    | ±âŸ | 
    - ¸¶¿ì½º¿¡¼ ½Ç½ÃÇÑ Àå±â´ë·® °æ±¸ Åõ¿©(ÀÓ»ó¿ë·®ÀÇ ¾à 75-375¹è)ÈÄ, ƯÈ÷ ¼öÄÆ¿¡¼ °£Á¾¾ç ¹ß»ýÁß°¡°¡ ÀÎÁ¤µÇ¾ú´Ù´Â º¸°í°¡ ÀÖ´Ù. ¶ÇÇÑ ·§Æ®¿¡¼ ½Ç½ÃÇÑ Àå±â ´ë·® °æ±¸Åõ¿©(ÀÓ»ó¿ë·®ÀÇ ¾à 10-100¹è)ÈÄ,°©»ó¼± Á¾¾ç ¹ß»ý Áõ°¡°¡ ÀÎÁ¤µÇ¾ú´Ù´Â º¸°í°¡ ÀÖ´Ù.
 - °í¿ë·®ÀÇ µ¿¹°½ÇÇè(¸¶¿ì½º)¿¡¼ ÀÌ ¾àÀÌ ³¸ð¼¼Æ÷ÀÇ °¨¼öºÐ¿À» Áö¿¬½ÃŲ´Ù´Â º¸°í°¡ ÀÖÀ¸¸ç, Æ÷À¯·ùÀÇ ¹è¾ç¼¼Æ÷¸¦ ÀÌ¿ëÇÑ in vitro ½ÃÇè¿¡¼ ÀÌ ¾àÀÌ ¿°»öüÀÇ ÀÌ»óºÐ¸®¸¦ À¯¹ßÇÑ´Ù´Â º¸°í°¡ ÀÖÀ¸¹Ç·Î ÀÌ ¾à Åõ¿© ÁßÀÇ È¯ÀÚ´Â ÇÇÀÓÀ» ÇÒ °Í.  ¶ÇÇÑ Àû¾îµµ Åõ¿©ÁßÁö ÈÄ ¿©¼ºÀº 1°³¿ù, ³²¼ºÀº 6°³¿ù°£ ÇÇÀÓÇÒ °Í.
 
  | 
   
  
  
  
  
   
    | Related FDA Approved Drug | 
    
      
      ±âÁØ ¼ººÐ: GRISEOFULVINFULVICIN P/G (GRISEOFULVIN, ULTRAMICROCRYSTALLINE) 
FULVICIN P/G 165 (GRISEOFULVIN, ULTRAMICROCRYSTALLINE) 
FULVICIN P/G 330 (GRISEOFULVIN, ULTRAMICROCRYSTALLINE) 
FULVICIN-U/F (GRISEOFULVIN, MICROCRYSTALLINE) 
GRIFULVIN V (GRISEOFULVIN, MICROCRYSTALLINE) 
GRISACTIN (GRISEOFULVIN, MICROCRYSTALLINE) 
GRISACTIN ULTRA (GRISEOFULVIN, ULTRAMICROCRYSTALLINE) 
GRISEOFULVIN (GRISEOFULVIN, MICROCRYSTALLINE) 
GRIS-PEG (GRISEOFULVIN, ULTRAMICROCRYSTALLINE) 
ULTRAGRIS-165 (GRISEOFULVIN, ULTRAMICROCRYSTALLINE) 
ULTRAGRIS-330 (GRISEOFULVIN, ULTRAMICROCRYSTALLINE) 
        
     | 
      
  
  
      							
 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¤º¸¿ä¾à | 
                 
	         
	       | 
	           	    
	     |  
	    | 
  
    µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
    
  
  
    
  
   |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ÄÚµå ¹× ºÐ·ùÁ¤º¸ | 
                 
	         
	       | 
	           	    
	     |  
	    | 	 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¦Ç°Á¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	     |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | º¹¾àÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
   
    | LACTmed ¹Ù·Î°¡±â | 
    
      
        [¹Ù·Î°¡±â]
     | 
     
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
       
     | 
     
  
  
       
  
  
   
    | º¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
                                                          															
  
   
  
  
   
    | ÀӺο¡´ëÇÑÅõ¿© | 
    
      
      
        
	      
	      
	        | *  | 
	        
	          ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù. 
	         | 
	         
	       
	       | 
	   
	  
	    |   | 
	   
	  
	    
	      FDA : Cµî±Þ 
				        	
					  
					
	   | 
	  
	  
	  
	     
	     
	     
	     
	     
	     
	   | 
	 
	
	  
	      
	      
	        | *  | 
	        
	          »ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
	         | 
	         
	      
	        | *  | 
	        
	          ¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
	         | 
	         
	       
	   | 
	 
       
     | 
   
  
  
  	   
  
  	   
  
  	   
  
  
     
      | Pharmacokinetics | 
      
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
      
       |   
     
  
  
  
  
  
  
  
   
    | º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ | 
    
      [º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
     | 
   
  	
  
  
  
   
    | º¹¾à¶óº§ | 
    
    
    
      | À̹ÌÁö | 
      º¹¾à¼³¸í | 
     
    
    
        | 
      ÀÓ»êºÎ ¶Ç´Â ÀӽŰèȹÁß º¹¿ë±ÝÁö | 
     
    
       | 
     
    
     |  
    
      
	
	  
            | *  | 
	    º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. | 
	   
	  
            | *  | 
	    º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. | 
	   
	  
            | *  | 
	    ±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. | 
	   
	   
     |   
     | 
   
  	
  
  
  
   
    | º¸°ü»ó ÁÖÀÇ | 
    
      
    	
     | 
   
  
  
   
    | Á¶Á¦½Ã ÁÖÀÇ | 
    
      
    	
     | 
      
 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ½É»çÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	     |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | ÇмúÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
    | DUR (ÀǾàǰ»ç¿ëÆò°¡) | 
    º´¿ë±Ý±â :
     
	 °í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
	 
	  [»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]										
	  ¿¬·É´ë±Ý±â :
      °í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
      
       [¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
       
       
        
        
     | 
   
  
   
    | µ¶¼ºÁ¤º¸ | 
    Griseofulvin¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â 
  Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do  | 
   
  
   
    | Mechanism of Action | 
    
       Griseofulvin¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Griseofulvin is fungistatic, however the exact mechanism by which it inhibits the growth of dermatophytes is not clear. It is thought to inhibit fungal cell mitosis and nuclear acid synthesis. It also binds to and interferes with the function of spindle and cytoplasmic microtubules by binding to alpha and beta tubulin. 
     | 
   
  
   
    | Pharmacology | 
     
       Griseofulvin¿¡ ´ëÇÑ Pharmacology Á¤º¸ Griseofulvin is a mycotoxic metabolic product of Penicillium spp. It was the first available oral agent for the treatment of dermatophytoses and has now been used for more than forty years. Griseofulvin is fungistatic with in vitro activity against various species of Microsporum Epidermophyton, and Trichophyton. It has no effect on bacteria or on other genera of fungi. Following oral administration, griseofulvin is deposited in the keratin precursor cells and has a greater affinity for diseased tissue. The drug is tightly bound to the new keratin which becomes highly resistant to fungal invasions. 
     | 
   
  
   
    | Protein Binding | 
    
       Griseofulvin¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available 
     | 
   
  
   
    | Half-life | 
    
       Griseofulvin¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 9-21 hours 
     | 
   
  
   
    | Absorption | 
    
       Griseofulvin¿¡ ´ëÇÑ Absorption Á¤º¸ Poorly absorbed from GI ranging from 25 to 70% of an oral dose. Absorption is significantly enhanced by administration with or after a fatty meal. 
     | 
   
  
   
    | Pharmacokinetics | 
    
       GriseofulvinÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
- Èí¼ö : Áö¿ë¼º À½½Ä¹°°ú °°ÀÌ º¹¿ëÇÏ´Â °æ¿ì Áõ°¡ÇÑ´Ù.
	
	   - Griseofulvin microsize : ´Ù¾çÇÏ´Ù (°æ±¸ ¿ë·®ÀÇ 25-70%)
	   
 - Griseofulvin ultramicrosize : °ÅÀÇ ¿ÏÀüÈ÷ Èí¼öµÈ´Ù.
	
  
 - ºÐÆ÷ : ÅÂ¹Ý Åë°ú
 - ´ë»ç : ´ëºÎºÐÀÌ °£¿¡¼ ´ë»çµÈ´Ù.
 - ¹Ý°¨±â : 9-22 ½Ã°£
 - ¼Ò½Ç : 1% ¹Ì¸¸ÀÌ ¹Ìº¯Èü·Î ½Å¹è¼³, ÀϺδ º¯¹è¼³
  
 
	 
	
     | 
   
  
   
    | Biotransformation | 
    
       Griseofulvin¿¡ ´ëÇÑ Biotransformation Á¤º¸ Primarily hepatic with major metabolites being 6-methyl-griseofulvin and its glucuronide conjugate. 
     | 
   
  
   
    | Toxicity | 
    
       Griseofulvin¿¡ ´ëÇÑ Toxicity Á¤º¸ Side effects are minor: headaches, gastrointestinal reactions and cutaneous eruptions 
     | 
   
  
   
    | Drug Interactions | 
    
       Griseofulvin¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Amobarbital	The barbiturate decreases the effect of griseofulvinAprobarbital	The barbiturate decreases the effect of griseofulvinButalbital	The barbiturate decreases the effect of griseofulvinButabarbital	The barbiturate decreases the effect of griseofulvinButethal	The barbiturate decreases the effect of griseofulvinDihydroquinidine barbiturate	The barbiturate decreases the effect of griseofulvinHeptabarbital	The barbiturate decreases the effect of griseofulvinHexobarbital	The barbiturate decreases the effect of griseofulvinMethohexital	The barbiturate decreases the effect of griseofulvinMethylphenobarbital	The barbiturate decreases the effect of griseofulvinTalbutal	The barbiturate decreases the effect of griseofulvinSecobarbital	The barbiturate decreases the effect of griseofulvinQuinidine barbiturate	The barbiturate decreases the effect of griseofulvinPrimidone	The barbiturate decreases the effect of griseofulvinPhenobarbital	The barbiturate decreases the effect of griseofulvinPentobarbital	The barbiturate decreases the effect of griseofulvinWarfarin	Griseofulvin decreases the anticoagulant effectAcenocoumarol	Griseofulvin decreases the anticoagulant effectDicumarol	Griseofulvin decreases the anticoagulant effectAnisindione	Griseofulvin decreases the anticoagulant effectAspirin	Anticipate decrease of ASA efficiency in presence of griseofulvinChlorotrianisene	The enzyme inducer decreases the effect of the hormonesClomifene	The enzyme inducer decreases the effect of the hormonesCyclosporine	Griseofulvin decreases the effect of cyclosporineDiethylstilbestrol	The enzyme inducer decreases the effect of the hormonesEstradiol	The enzyme inducer decreases the effect of the hormonesEstriol	The enzyme inducer decreases the effect of the hormonesConjugated Estrogens	The enzyme inducer decreases the effect of the hormonesEstrone	The enzyme inducer decreases the effect of the hormonesEstropipate	The enzyme inducer decreases the effect of the hormonesMedroxyprogesterone	The enzyme inducer decreases the effect of the hormonesMegestrol	The enzyme inducer decreases the effect of the hormonesEthinyl Estradiol	This product may cause a slight decrease of contraceptive effectQuinestrol	The enzyme inducer decreases the effect of the hormonesMestranol	This product may cause a slight decrease of contraceptive effectNorethindrone	This product may cause a slight decrease of contraceptive effect 
     | 
   
  
   
    CYP450  Drug Interaction | 
    
      [CYP450 TableÁ÷Á¢Á¶È¸] 
     | 
   
  
   
    | Food Interaction | 
    
       Griseofulvin¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take this medication with a high fat meal, fatty foods increase bioavailability. Avoid alcohol. 
     | 
   
  
   
    | Drug Target | 
    
      
      [Drug Target]
     | 
   
  
   
    | Description | 
    
       Griseofulvin¿¡ ´ëÇÑ Description Á¤º¸ An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. [PubChem] 
     | 
   
  
   
    | Dosage Form | 
    
       Griseofulvin¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Suspension	OralTablet	Oral 
     | 
   
  
   
    | Drug Category | 
    
       Griseofulvin¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antibacterial AgentsAntibiotics, Antifungal 
     | 
   
  
   
    | Smiles String Canonical | 
    
       Griseofulvin¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ COC1=CC(OC)=C(Cl)C2=C1C(=O)C1(O2)C(C)CC(=O)C=C1OC 
     | 
   
  
   
    | Smiles String Isomeric | 
    
       Griseofulvin¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC 
     | 
   
  
   
    | InChI Identifier | 
    
       Griseofulvin¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C17H17ClO6/c1-8-5-9(19)6-12(23-4)17(8)16(20)13-10(21-2)7-11(22-3)14(18)15(13)24-17/h6-8H,5H2,1-4H3/t8-,17+/m1/s1 
     | 
   
  
   
    | Chemical IUPAC Name | 
    
       Griseofulvin¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (2S,5'R)-7-chloro-3',4,6-trimethoxy-5'-methylspiro[1-benzofuran-2,4'-cyclohex-2-ene]-1',3-dione 
     | 
   
    
  |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | »ç¿ëÀÚÄÁÅÙÃ÷ | 
                             
	         
	       | 
	           	  
       |  
	     |  
	   
	     	
 
  | 
   
   
     | 
   
  
    
      
        
          
            
              - 
                ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2015-03-19
              
 
              - 
                
                º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
                
              
     
             
         |                 
       
     |       
          
                
                    
                       ¾Ë¸² | 
                       
                      »ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.  | 
                    
                    | 
               
      
      
                
                    
                       °æ°í | 
                     
                      µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù. 
                          Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â 
                          Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
                            ¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
                          ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
 | 
                    
                    | 
               
  
 
  
    ¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é 
    ¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
   
  
 
  º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
 
  [ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â]       Á¦¸ñ ¾øÀ½ 
 
    
    2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
    
    1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ  º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
    ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
          
    
    
    
    2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
    ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
 
 
 
   
  |  
             
             | 
         
         
         | 
         |